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Abstract: Bipolar affective disorder is a disabling illness with substantial morbidity and many 
management challenges. Traditional mood stabilizers such as lithium, valproate, and carbam-
azepine are often inadequate in controlling symptoms both during the acute and maintenance 
phase of treatment. Aripiprazole is a second-generation antipsychotic with a unique mechanism 
of action. Evidence suggests that it is effective in acute manic and mixed states. There are limited 
data to suggest its efficacy as a maintenance agent. Future studies will be needed to better define 
the role of aripiprazole relative to other traditional pharmacologic agents.
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Introduction
Amongst people aged 15–44 years, bipolar affective disorder (BPAD) is the sixth 
leading cause of medical disability worldwide and associated with a greater degree 
of impairment than chronic medical conditions such as osteoarthritis, asthma, and 
diabetes.1 Patients report significant levels of impairment in family relationships, 
social relationships, and employment.2 BPAD patients have higher levels of impair-
ment and rates of rehospitalization relative to unipolar depression patients.3 Cost of 
care has been estimated at USD$45 billion.4 The monthly cost per patient of treating 
this illness have been estimated at USD$1600, and exceeds that of coronary artery 
disease, unipolar depression, and diabetes.5
Epidemiology
BPAD is a rare yet severe psychiatric illness with an estimated lifetime prevalence of 
1.6%.6 However, estimates from community samples frequently miss milder forms of 
BPAD resulting in the underestimation of prevalence rates.1 Expanding the diagnostic 
criteria to include subthreshold symptoms of mania and hypomania has resulted in preva-
lence estimates as high as 11.5%.7 An estimated 40% of patients diagnosed with major 
depressive disorder are reported to have subthreshold hypomanic symptoms.8,9 Baseline 
hypomanic symptoms are associated with younger age at onset, a family history of BPAD, 
greater levels of impairment, and increased psychiatric comorbidity.9 An estimated 20% 
of patients initially diagnosed with major depressive disorder will eventually go on to 
have a manic or hypomanic episode and the baseline presence of subtheshold hypomanic 
symptoms is a significant predictor of subsequent mania or hypomania.10
There is no gender partiality, although women have been reported to experience 
more depressive episodes over the course of illness as opposed to manic episodes.11–13 
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Typical age of onset is between the ages of 15 and 19 years, 
and more than 50% of patients experience their first affective 
symptoms during childhood or adolescence.12,14
The elevated cost of care of this disorder is in part due 
to the extensive comorbidity of this population. The Epide-
miologic Catchment Area Survey found an estimated 46% of 
patients used alcohol or were alcohol dependent, 41% used 
drugs or were drug dependent, 21% had panic disorder, and 
21% had obsessive-compulsive disorder.15–17
Diagnostic and management 
challenges
Accurate diagnosis continues to be a barrier to adequate treat-
ment. The high rate of comorbidity with substance use makes 
it difficult to distinguish between mood lability secondary 
to drug and alcohol use versus a true bipolar spectrum. In 
the setting of substance abuse, bipolar disorder may be over-
diagnosed. Goldberg et al found that only 33% of patients 
with active substance abuse suspected of having bipolar 
disorder met criteria after formal interview.18  High rates of 
misdiagnosis of unipolar depression have been reported.19
However, additional literature suggests that bipolar disor-
der may be underdiagnosed. Ghaemi et al found that 40% of 
bipolar patients were initially misdiagnosed, most commonly 
with major depressive disorder, and waited an average of 
7.5 years before an accurate diagnosis was given.20 Other 
studies have also reported high rates of misdiagnosis with 
patients most commonly labeled with unipolar depression.2 
Impediments to accurate diagnosis include failure to recog-
nize hypomanic symptoms and frequent initial presentation 
with depressive features. 21 Over 50% of BPAD patients will 
initially present with a depressive episode.22
Failure to accurately diagnose bipolar disorder can lead 
to improper treatment. Most frequently, patients are given 
antidepressants without mood stabilizers placing them at 
increased risk for switching into mania and/or rapid cycling as 
well as poor response to depressive symptoms.21 Additionally, 
bipolar disorder is associated with a higher risk of suicide 
than any other axis I disorder. An estimated 25%–50% of 
bipolar patients attempt suicide, with the majority of attempts 
occurring during depressive episodes.22,23
Maintenance therapies have traditionally focused on 
mood stabilizers including lithium, valproic acid, carbam-
azepine, and, recently, lamotrigine. All agents have been 
shown to be effective relative to placebo in preventing 
relapses and typically need to be used in combination to 
control symptoms.24 Lithium has long been considered the 
gold standard of therapy. Relative to placebo, lithium use 
reduces the rates of manic or hypomanic episodes by 64% 
and depressive episodes by 30%–50%.25 However, relapse 
rates on lithium have ranged from 20% to 40%.26 Given the 
high relapse rate and extensive morbidity associated with 
this illness, additional therapies are needed.
The atypical antipsychotics have increasingly been used 
as an add-on and even monotherapy in bipolar spectrum 
disorders. Olanzapine was the first agent to gain US Food 
and Drug Administration approval for bipolar maintenance 
therapy. Relative to placebo, the relative risk of relapse on 
olanzapine for any episode has been estimated to be 0.6 and 
the number needed to treat, 4.2.27 Olanzapine has shown simi-
lar efficacy to lithium and divalproex.27 However, concerns 
about the metabolic side effects of olanzapine can lead to 
treatment discontinuation or adverse health outcomes.27
Pharmacodynamics and 
pharmacokinetics of aripiprazole
Aripiprazole, a quinolinone antipsychotic, is currently 
the only US Food and Drug Administration–approved 
atypical antipsychotic that is characterized uniquely as a 
partial agonist at the dopamine D2 receptor and serotonin 
5-HT1A receptor.28 Agonism of the 5-HT1A receptor is 
thought to activate a cascade that results in inhibition of 
cortical pyramidal neurons, hormonal regulation, and may 
affect depression, anxiety, and cognition.29 Agonism of D2 
receptor is thought to mediate psychosis and the dopamine-
reward system in the brain. Antagonism of the D2 receptor 
is thought to be responsible for antipsychotic efficacy, 
as well as undesired effects including affective blunting, 
worsening cognition, akathisia, parkinsonism, and hyper-
prolactinemia. Conventional and other atypical antipsychot-
ics are full dopamine D2 receptor and serotonin 5-HT1A 
receptor antagonists that do not allow receptor output.29 
Aripiprazole, as a partial agonist, can partially activate the 
receptor to a lesser extent than a full agonist, yet attenuate, 
but not completely block, the receptor output.29 Through 
this mechanism, it creates a stabilizing balance between the 
D2 receptor and 5-HT1A receptor output.29 Similar to other 
atypical antipsychotics, aripiprazole antagonizes serotonin 
5-HT2A receptors, which balances D2 receptor blockade 
and attenuates extrapyramidal side effects. Aripiprazole 
exhibits high receptor-binding affinity to dopamine D2, 
D3, serotonin 5-HT1A, 5-HT2A, and 5-HT7 receptors.28–30 
This activity is thought to mediate psychosis, depression, 
anxiety, cognition, sleep, mood, learning, and memory.30 
It has moderate affinity for α-adrenergic α1, α2C, and his-
tamine H1 receptors, which are associated with balancing 
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dopamine blockade, hypotension, sedation, and cognitive 
impairment.28,30 Aripiprazole has no appreciative affinity 
for muscarinic M1 cholinergic receptors that relate to low 
anticholinergic side-effect potential.28,30
Aripiprazole is metabolized hepatically primarily 
via cytochrome P-450 (CYP) 2D6 and 3A4 isoenzymes 
to its active metabolite, dehydroaripiprazole.28 This 
metabolite is thought to have receptor activity similar to 
that of aripiprazole but has an extended half-life. Steady-
state serum concentrations consist of approximately 
60% aripiprazole and 40% dehydroaripiprazole. The 
recommended adult dose for aripiprazole monotherapy 
treatment of bipolar I is 15 mg once daily, which may be 
titrated to 30 mg once daily if needed.28 Children aged 
.10 years may be initiated at 2 mg aripiprazole daily and 
titrated to a target maintenance dose of 10 mg aripiprazole 
daily.28 Concomitant therapy with CYP 3A4 inducers, 
including carbamazepine, may increase clearance and lower 
serum concentrations of aripiprazole and dehydroaripipra-
zole by approximately 70%.28 Effective doses of aripipra-
zole may need to be titrated to double the recommended 
maintenance dose when coadministered with strong CYP 
3A4 ind  ucers. Coadministration with CYP 2D6 inhibitors 
including quinidine and fluoxetine may increase serum 
concentrations of aripiprazole by approximately 112% 
and reduce serum concentrations of dehydroaripiprazole 
by 35%.28 To compensate for these effects, effective doses 
of aripiprazole may need to be reduced by half when coad-
ministered with CYP 3A4 inhibitors, such as ketoconazole 
and some antiretrovirals, or when coadministered with 
2D6 inhibitors such as quinidine and fluoxetine. Currently, 
no dose adjustments are recommended for the elderly or 
individuals with hepatic or renal impairment.
Aripiprazole drug labeling currently includes pharma-
cogenomic dosing recommendations based on CYP 2D6 
isoenzyme polymorphisms. Poor metabolizers at CYP 2D6 
would result in an 80% increase in exposure to aripiprazole, 
and these individuals should have initial doses reduced 
by half.28 No initial dose adjustment is recommended for 
extensive metabolizers at CYP 2D6. The average half-life of 
aripiprazole is 75 hours for extensive CYP 2D6 metabolizers 
and 146 hours for poor metabolizers.28 The long half-life of 
aripiprazole allows for once-daily dosing of the drug. Steady-
state serum concentrations can be reached in approximately 
2 weeks but time to reach steady state may be doubled in 
CYP 2D6 poor metabolizers. Individuals’ time to steady state 
may be considered when assessing efficacy and appropriate 
dose titrations of aripiprazole.
Clinical data
Aripiprazole stands apart from other atypical antipsychotics 
because of its unique mechanism of action through partial 
agonism at the D2 and D3 receptors as well as its 5HT2A 
antagonist properties and partial agonism at the 5HT1A 
receptor. It is less commonly associated with the metabolic 
side effects of olanzapine.31 Consequently, it is a good can-
didate for acute and maintenance treatment of BPAD.
Several studies have demonstrated aripiprazole to be 
effective in the acute treatment of mania and mixed states 
(summarized in Table 1).32–37 Sachs et al randomized 
272 hospitalized patients with manic or mixed episodes 
to aripiprazole or placebo in a 3-week trial. Response was 
significantly higher with aripriprazole (53%) relative to 
placebo (32%) and this difference was evident as early as 
day 4. Discontinuation of treatment due to adverse effects 
was similar between the two groups. Target dosing was 
30 mg/day of aripriprazole and was maintained in 85% 
of patients.33 Similarly, in a 12-week trial of 347 manic or 
mixed patients, Vieta et al found superior rates of response 
and tolerability in aripriprazole treated patients compared to 
those randomized to haloperidol. Response rates for aripip-
razole treated patients were 50% compared to 28% of halo-
peridol patients.32 By week 12, 51% of aripiprazole-treated 
patients, compared with 29% of haloperidol-treated patients, 
remained on therapy. Extrapyramidal side effects were also 
significantly higher in the haloperidol-treated group. Vieta 
et al showed apripriprazole produces significantly higher 
rates of response and remission compared with placebo when 
used as an adjuvant therapy to lithium and valproate during 
a 6-week double-blind placebo-controlled study involving 
384 manic or mixed patients. At the end of 6 weeks, 50% 
of aripriprazole-treated patients were classified as remitters 
based on a Young Mania Rating Scale score ,12 versus 
36% of placebo-treated patients. Mean aripiprazole dose 
was 19 mg/day. Aripiprazole-treated patients reported 
higher incidence of extrapyramidal symptoms. There 
were no differences between the aripiprazole and placebo 
groups on metabolic parameters.34 In a randomized double-
blind placebo-controlled comparative study with lithium, 
aripiprazole-treated patients demonstrated significantly 
greater response rates than placebo and similar rates to those 
observed with lithium at the 3-week end point.35
The data on the use of aripiprazole in the maintenance 
phase are sparse. Following the 6–18 week stabilization 
phase, Keck et al38 randomized 161 recently manic or 
mixed patients to receive monotherapy with aripiprazole 
(78) or p  lacebo (83) for an additional 100 weeks. The only 
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concomitant medications allowed were lorazepam 2 mg/day 
during the first month, 1 mg/day during the second month, 
and 1 mg/day up to four times per week for the remainder 
of the study. Anticholingerics were also allowed. Primary 
endpoint was time to relapse for a mood episode. Relapse 
was defined as hospitalization due to mood episode and/or 
addition or increase in psychotropic medication other than the 
study drug for mood symptoms. Mean dose of aripiprazole 
was 24 mg. On data analysis, aripiprazole-treated patients had 
a significantly longer time to relapse into mania than placebo-
treated patients. No differences were observed for depressive 
episodes. Fifty two percent of the aripiprazole- versus 33% 
of placebo-treated patients experienced a relapse.38 No differ-
ences were observed between the groups in lipid, glucose, or 
weight changes. In a 46-week open-label extension follow-
ing a 6-week double-blind phase of adjunctive aripiprazole 
to lithium or valproate in partial responders with bipolar 
mania, Vieta et al found adjunctive aripiprazole to lead to 
significant improvements in Young Mania Rating scores and 
Montgomery-Asberg Depression Scale.39 Mean aripiprazole 
dose was 18 mg/day. Other studies have also demonstrated 
aripiprazole to be effective as adjunctive therapy in patients 
with an inadequate response to lithium or valproic acid.40
Conclusion and future directions
The use of aripiprazole in the acute phase of manic and mixed 
episodes seems to be supported by the literature and is in 
line with common practice patterns where a primary mood 
stabilizer and antipsychotic are often started simultaneously. 
However, the dearth of data on aripiprazole as maintenance 
agents makes it difficult to recommend this during the main-
tenance phase over more established prophylactic agents such 
as lithium, valproic acid, and carbamazepine.
Although studies to date have demonstrated the potential 
for aripiprazole in the acute treatment phase and maintenance 
treatment of BPAD, additional data are needed to better clar-
ify its role in the treatment of this disabling disorder, particu-
larly in the maintenance phase. Due to the lesser   incidence of 
Table 1 Aripiprazole in the acute treatment of bipolar affective disorder, manic, and mixed states
Study (reference  
number)
Patients, n Length Treatment Endpoint Result
30 347 manic  
or mixed
12 weeks Aripiprazole, halolperidol  
(double blind)
Response via YMRS  Aripiprazole showed significantly  
greater response rate relative   
to haloperidol. 
Greater incidence of EPS in  
haloperidol group
31 272 manic  
or mixed
3 weeks Aripiprazole or placebo  
(double blind)
Mean change in YMRS,  
response via YMRS
Significantly greater YMRS  
reductions and response observed  
with aripiprazole. 
No difference between groups in  
discontinuation secondary to  
adverse effects
33 480 manic  
or mixed
3 weeks Aripiprazole, lithium,  
or placebo (double blind)
Mean change in YMRS  Significantly greater reduction  
in YMRS in ariprazole vs placebo,  
similar reductions  
in aripiprazole relative to lithium
34 485 manic  
or mixed
3 weeks Aripiprazole, placebo,  
or haloperidol (double  
blind)
Mean change in YMRS  Significant reductions in YMRS  
relative to placebo, similar to  
haloperidol.  
Aripriprazole associated with lower 
incidence of EPS than haloperidol
35 262 manic  
or mixed
3 weeks Aripiprazole or placebo  
(double blind)
Mean change in YMRS,  
response via YMRS
Aripiprazole treated patients had  
significantly greater mean reductions/ 
response rates. 
Discontinuation secondary to adverse 
effects did not differ between groups
39 384 manic  
or mixed
6 weeks Adjunctive aripiprazole vs  
placebo to lithium/valproate  
(double blind)
Reductions in YMRS,  
Response/remission  
via YMRS
Significant reductions in YMRS, 
significantly greater response/ 
remission in aripiprazole treated  
patients
Abbreviations: EPS, Extrapyramidal symptoms; YMRS, Young Mania Rating Scale.
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metabolic side effects, aripiprazole is an attractive alternative 
to olanzapine, yet there are no head-to-head trials comparing 
either these two agents or aripiprazole to other atypical agents 
used in BPAD such as quetiapine or risperidone. Long-term 
maintenance studies comparing aripiprazole to lamotrigine 
and carbamazepine are also lacking. Additionally, no studies 
have been done comparing aripiprazole in combination with 
a mood stabilizer with two primary mood stabilizers such 
as lithium and valproate or carbamazepine. No research has 
examined its role in BPAD II.
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